Platelet adhesion and human umbilical vein endothelial cell cytocompatibility of biodegradable segmented polyurethanes prepared with 4,4′-methylene bis(cyclohexyl isocyanate),poly(caprolactone) diol and butanediol or dithioerythritol as chain extenders
Restricted accessResearch articleFirst published online August, 2013
Platelet adhesion and human umbilical vein endothelial cell cytocompatibility of biodegradable segmented polyurethanes prepared with 4,4′-methylene bis(cyclohexyl isocyanate),poly(caprolactone) diol and butanediol or dithioerythritol as chain extenders
Biodegradable segmented polyurethanes were prepared with poly(caprolactone) diol as a soft segment, 4,4′-methylene bis(cyclohexyl isocyanate) (HMDI) and either butanediol or dithioerythritol as chain extenders. Platelet adhesion was similar in all segmented polyurethanes studied and not different from Tecoflex® although an early stage of activation was observed on biodegradable segmented polyurethane prepared with dithioerythritol. Relative viability was higher than 80% on human umbilical vein endothelial cells in contact with biodegradable segmented polyurethane extracts after 1, 2 and 7 days. Furthermore, both biodegradable segmented polyurethane materials supported human umbilical vein endothelial cell adhesion, spreading, and viability similar to Tecoflex® medical-grade polyurethane. These biodegradable segmented polyurethanes represent promising materials for cardiovascular applications.
ZdrahalaRJZdrahalaIJ. Biomedical applications of polyurethanes: a review of past promises, present realities, and a vibrant future. J Biomater Appl1999; 14(1): 67–90.
2.
FieldsCCassanoAAllenC. Endothelial cell seeding of a 4-mm I.D. polyurethane vascular graft. J Biomater Appl2002; 17(1): 45–70.
3.
GrenierSSandigMHoldsworthDW. Interactions of coronary artery smooth muscle cells with 3D porous polyurethane scaffolds. J Biomed Mater Res2009; 89A(2): 293–303.
4.
HeijkantsRGJCvan CalckRVvan TienenTG. Uncatalyzed synthesis, thermal and mechanical properties of polyurethanes based on poly(-caprolactone) and 1,4-butane diisocyanate with uniform hard segment. Biomaterials2005; 26(20): 4219–4228.
5.
HassanMKMauritzKAStoreyRF. Biodegradable aliphatic thermoplastic polyurethane based on poly(ɛ-caprolactone) and L-lysine diisocyanate. J Polym Sci Part A: Polym Chem2006; 44(9): 2990–3000.
GornaKGogolewskiS. Biodegradable polyurethanes for implants. II. In vitro degradation and calcification of materials from poly(ɛ-caprolactone)–poly(ethylene oxide) diols and various chain extenders. J Biomed Mater Res2002; 60(4): 592–606.
SaadGRLeeYJSeligerH. Synthesis and characterization of biodegradable poly(ester-urethanes) based on bacterial poly(R-3-hydroxybutyrate). J Appl Polym Sci2002; 83(4): 703–718.
10.
Gorna K and Gogolewski S. Novel biodegradable polyurethanes for medical applications. In: Agrawal CM, Parr JE and Lin ST (eds) Synthetic bioresorbable polymers for implants. ASTM Special Technical Publication. West Conshohocken, PA: American Society for Testing and Material. 2000, pp. 39–57.
11.
SkarjaGAWoodhouseKA. Structure-property relationships of degradable polyurethane elastomers containing an amino acid-based chain extender. J Appl Polym Sci2000; 75(12): 1522–1534.
12.
Woodhouse KA and Skarja GA. Biodegradable polyurethanes. Patent 6,221,997B1, USA, 2001.
13.
SarkarDYangJ-CKlettlingerN. Blends of L-tyrosine based polyurethanes for biomaterial applications. eXPRESS Polym Lett2007; 1(11): 724–733.
14.
Marcos-FernándezAAbrahamGAValentínJL. Synthesis and characterization of biodegradable non-toxic poly(ester-urethane-urea)s based on poly(ɛ-caprolactone) and amino acid derivatives. Polymer2006; 47(3): 785–798.
15.
Gogolewski S. Biocompatible-biodegradable polyurethane materials with controlled hydrophobic to hydrophilic ratio. Patent 2008/0262613 A1, USA, 2008.
16.
ZhangJDollBABeckmanEJ. A biodegradable polyurethane-ascorbic acid scaffold for bone tissue engineering. J Biomed Mater Res2003; 67A(2): 389–400.
17.
Chan-ChanLHSolis-CorreaRVargas-CoronadoRF. Degradation studies on segmented polyurethanes prepared with HMDI, PCL and different chain extenders. Acta Biomater2010; 6(6): 2035–2044.
18.
PoussardLBurelFCouvercelleJP. Hemocompatibility of new ionic polyurethanes: influence of carboxylic group insertion modes. Biomaterials2004; 25(17): 3473–3483.
19.
DuanXLewisRS. Improved haemocompatibility of cysteine-modified polymers via endogenous nitric oxide. Biomaterials2002; 23(4): 1197–1203.
20.
FrostMCMeyerhoffME. Synthesis, characterization, and controlled nitric oxide release from S-nitrosothiol-derivatized fumed silica polymer filler particles. J Biomed Mater Res2005; 72A(4): 409–419.
21.
KawamotoYNakaoAItoY. Endothelial cells on plasma-treated segmented-polyurethane: adhesion strength, antithrombogenicity and cultivation in tubes. J Mater Sci: Mater Med1997; 8(9): 551–557.
22.
ÖzkucurNRichterEWetzelC. Biological relevance of ion energy in performance of human endothelial cells on ion-implanted flexible polyurethane surfaces. J Biomed Mater Res2010; 93A(1): 258–268.
23.
SidouniFZNurdinNChabrecekP. Surface properties of a specifically modified high-grade medical polyurethane. Surf Sci2001; 491(3): 355–369.
24.
LiJDingMFuQ. A novel strategy to graft RGD peptide on biomaterials surfaces for endothelization of small-diamater vascular grafts and tissue engineering blood vessel. J Mater Sci: Mater Med2008; 19(7): 2595–2603.
25.
HsuS-hSunS-hChenDC. Improved retention of endothelial cells seeded on polyurethane small-diameter vascular grafts modified by a recombinant RGD-containing protein. Artif Organ2003; 27(12): 1068–1078.
26.
ChuangT-WMastersKS. Regulation of polyurethane hemocompatibility and endothelialization by tethered hyaluronic acid oligosaccharides. Biomaterials2009; 30(29): 5341–5351.
27.
ChungT-WLiuD-ZWangS-Y. Enhancement of the growth of human endothelial cells by surface roughness at nanometer scale. Biomaterials2003; 24(25): 4655–4661.
